Corcept Therapeutics
(NASDAQ) CORT
Corcept Therapeutics Financials at a Glance
Market Cap
$4.45B
Revenue (TTM)
$761.41M
Net Income (TTM)
$99.08M
EPS (TTM)
$0.82
P/E Ratio
51.18
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$42.26
Volume
27,377
Open
$41.56
Price
$42.26
Volume
27,377
Open
$41.56
Previous Close
$42.26
Daily Range
$41.56 - $42.55
52-Week Range
$28.66 - $91.00
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$42.26
Volume
27,377
Open
$41.56
Previous Close
$42.26
Daily Range
$41.56 - $42.55
52-Week Range
$28.66 - $91.00
CORT News
CORT: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Corcept Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
730
CEO
Joseph K. Belanoff, MD
Website
www.corcept.comHeadquarters
Menlo Park, CA 94025, US
CORT Financials
Key Financial Metrics (TTM)
Gross Margin
98%
Operating Margin
6%
Net Income Margin
13%
Return on Equity
15%
Return on Capital
7%
Return on Assets
12%
Earnings Yield
1.95%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$4.45B
Shares Outstanding
106.37M
Volume
27.38K
Short Interest
0.00%
Avg. Volume
1.99M
Financials (TTM)
Gross Profit
$748.43M
Operating Income
$44.80M
EBITDA
$68.35M
Operating Cash Flow
$142.00M
Capital Expenditure
$211.00K
Free Cash Flow
$141.78M
Cash & ST Invst.
$372.15M
Total Debt
$6.11M
Corcept Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$202.13M
+11.1%
Gross Profit
$199.58M
+11.5%
Gross Margin
98.74%
N/A
Market Cap
$4.45B
N/A
Market Cap/Employee
$8.91M
N/A
Employees
500
N/A
Net Income
$24.29M
-20.1%
EBITDA
$10.39M
-59.6%
Quarterly Fundamentals
Net Cash
$366.05M
-2.8%
Accounts Receivable
$59.79M
+2.9%
Inventory
$12.87M
+3.7%
Long Term Debt
$5.02M
-17.8%
Short Term Debt
$1.08M
+30.8%
Return on Assets
11.84%
N/A
Return on Invested Capital
6.68%
N/A
Free Cash Flow
$38.40M
-35.1%
Operating Cash Flow
$38.45M
-35.2%